Journal
CHEMICAL RESEARCH IN TOXICOLOGY
Volume 28, Issue 7, Pages 1391-1397Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrestox.5b00208
Keywords
-
Funding
- European Research Council (CONNECT)
- European Union (FP7)
- Cosmetics Europe (DETECTIVE)
- Fund for Scientific Research, Flanders (FWO-Vlaanderen)
- Sao, Paulo Research Foundation, Brazil (FAPESP)
- University of sao Paulo, Brazil (USP)
- University Hospital of the Vrije Universiteit Brussel, Belgium (Willy Gepts Fonds UZ - VUB)
- Cosmetics Europe (HeMiBio)
Ask authors/readers for more resources
Drug-induced liver injury is a prominent reason for premarketing and postmarketing drug withdrawal and can be manifested in a number of ways, such as cholestasis, steatosis, and fibrosis. The mechanisms driving these toxicological processes have been well characterized and have been emdedded in adverse outcome pathway frameworks in recent years. This review evaluates these constructs and simultaneously illustrates their use in the preclinical testing of drug-induced liver injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available